Bright Minds Biosciences Inc.
DRUG
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.86% | 13.03% | -14.46% | -35.42% | -29.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.64% | 0.10% | -61.83% | -63.97% | -61.01% |
| Operating Income | -143.64% | -0.10% | 61.83% | 63.97% | 61.01% |
| Income Before Tax | -141.33% | 38.24% | 84.50% | 62.55% | 60.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -141.33% | 38.24% | 84.50% | 62.55% | 60.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.33% | 38.24% | 84.50% | 62.55% | 60.02% |
| EBIT | -143.64% | -0.10% | 61.83% | 63.97% | 61.01% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -38.43% | 63.11% | 86.67% | 65.79% | 65.67% |
| Normalized Basic EPS | -38.41% | 63.14% | 86.69% | 65.80% | 65.67% |
| EPS Diluted | -38.07% | 62.97% | 86.43% | 65.52% | 65.55% |
| Normalized Diluted EPS | -38.48% | 63.09% | 86.65% | 65.80% | 65.67% |
| Average Basic Shares Outstanding | 49.69% | 39.69% | 28.95% | 15.59% | 18.86% |
| Average Diluted Shares Outstanding | 52.57% | 42.70% | 32.09% | 15.59% | 18.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |